Natural Product (NP) Details
General Information of the NP (ID: NP5732) | |||||
---|---|---|---|---|---|
Name |
Osthole
|
||||
Synonyms |
Osthol; 484-12-8; Ostol; Ostole; 7-methoxy-8-(3-methylbut-2-en-1-yl)-2H-chromen-2-one; 7-Methoxy-8-isopentenylcoumarin; 2H-1-Benzopyran-2-one, 7-methoxy-8-(3-methyl-2-butenyl)-; 7-methoxy-8-(3-methylbut-2-enyl)chromen-2-one; NSC 31868; 8-(3-Methyl-2-butenyl)herniarin; 7-methoxy-8-(3-methyl-2-buten-1-yl)-2H-chromen-2-one; 7-METHOXY-8-(3-METHYL-2-BUTENYL)-COUMARIN; 7-methoxy-8-(3-methyl-2-butenyl)coumarin; UNII-XH1TI1759C; Coumarin, 7-methoxy-8-(3-methyl-2-butenyl)-; CHEMBL52229; XH1TI1759C; CHEBI:69832; NSC31868; 7-Methoxy-8-(3-methyl-but-2-enyl)-chromen-2-one; MFCD00076049; 7-methoxy-8-(3-methylbut-2-enyl)-2H-chromen-2-one; SMR000156202; Osthole (Osthol); A0O; Osthole,(S); Cnidium Fruit Extract; Spectrum_001542; SpecPlus_000946; Spectrum2_000723; Spectrum3_001645; Spectrum4_001687; Spectrum5_000334; Osthole, analytical standard; Oprea1_642606; Oprea1_873803; SCHEMBL50436; BSPBio_003369; KBioGR_001954; KBioSS_002022; ZINC566; MLS000574904; MLS001048988; MLS006011425; DivK1c_007042; SPECTRUM1504165; SPBio_000646; MEGxp0_000155; ACon1_002155; GTPL10302; HSDB 8479; KBio1_001986; KBio2_002022; KBio2_004590; KBio2_007158; KBio3_002589; DTXSID20197507; HMS2267O21; HMS3656A07; AMY40671; BCP10832; EBD33224; HY-N0054; ANW-50075; BBL013019; BDBM50240512; CCG-40172; CO0040; NSC-31868; s2337; STK396321; AKOS000277663; AC-8041; DS-0881; MCULE-5691054147; SDCCGMLS-0066780.P001; NCGC00095694-01; NCGC00095694-02; NCGC00095694-03; NCGC00095694-05; WLN: T66 BOVJ IO1 J2UY1&1; AK-35300; AB0021820; FT-0601535; N1825; O0426; ST50909221; SW219438-1; W1256; C09280; J10077; S-3211; 484O128; A827530; Osthole, primary pharmaceutical reference standard; SR-01000721624; Q-100535; Q4338679; SR-01000721624-4; BRD-K78294846-001-03-3; 7-Methoxy-8-(3-methyl-2-butenyl)-2H-chromen-2-one #; 7-methoxy-8-(3-methylbut-2-enyl)-1-benzopyran-2-one; Osthole, European Pharmacopoeia (EP) Reference Standard; 2H-1-Benzopyran-2-one, 7-methoxy-8-(3-methyl-2-butenyl)- (9CI); 1440642-68-1
Click to Show/Hide
|
||||
Species Origin | Angelica pubescens ... | Click to Show/Hide | |||
Angelica pubescens | |||||
Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H16O3
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(=CCC1=C(C=CC2=C1OC(=O)C=C2)OC)C
|
||||
InChI |
1S/C15H16O3/c1-10(2)4-7-12-13(17-3)8-5-11-6-9-14(16)18-15(11)12/h4-6,8-9H,7H2,1-3H3
|
||||
InChIKey |
MBRLOUHOWLUMFF-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 484-12-8
|
||||
Herb ID | |||||
SymMap ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | GABPA | Molecule Info | |||
Down-regulation | Expression | MKI67 | Molecule Info | |||
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SiHa | CVCL_0032 | Cervical squamous cell carcinoma | Homo sapiens | ||
Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | |||
In-vivo Model | SiHa/CDDP cells (1*106) suspended in cold PBS were subcutaneously injected to the right armpit of mice (female BALB/c nude mice). | |||||
Experimental
Result(s) |
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression. | |||||
Trastuzumab | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
In-vivo Model | N87 cells (1*107/per mouse) were inoculated subcutaneously into the right flank of female BALB/c nude mice. | |||||
Experimental
Result(s) |
Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Caki | Clear cell renal cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Interleukin-13 (IL13) | Molecule Info | [5] | |
Interleukin-5 (IL5) | Molecule Info | [5] | ||
Notch-1 receptor (NOTCH1) | Molecule Info | [6] | ||
STAT factor 3 (STAT3) | Molecule Info | [1] | ||
Tumor necrosis factor (TNF) | Molecule Info | [7] | ||
KEGG Pathway | Chemokine signaling pathway | Click to Show/Hide | ||
2 | HIF-1 signaling pathway | |||
3 | FoxO signaling pathway | |||
4 | Signaling pathways regulating pluripotency of stem cells | |||
5 | Jak-STAT signaling pathway | |||
6 | Prolactin signaling pathway | |||
7 | Adipocytokine signaling pathway | |||
8 | Toxoplasmosis | |||
9 | Hepatitis C | |||
10 | Hepatitis B | |||
11 | Measles | |||
12 | Epstein-Barr virus infection | |||
13 | Pathways in cancer | |||
14 | Viral carcinogenesis | |||
15 | Proteoglycans in cancer | |||
16 | MicroRNAs in cancer | |||
17 | Pancreatic cancer | |||
18 | Acute myeloid leukemia | |||
19 | Inflammatory bowel disease (IBD) | |||
20 | MAPK signaling pathway | |||
21 | Cytokine-cytokine receptor interaction | |||
22 | NF-kappa B signaling pathway | |||
23 | Sphingolipid signaling pathway | |||
24 | mTOR signaling pathway | |||
25 | Apoptosis | |||
26 | TGF-beta signaling pathway | |||
27 | Osteoclast differentiation | |||
28 | Antigen processing and presentation | |||
29 | Toll-like receptor signaling pathway | |||
30 | NOD-like receptor signaling pathway | |||
31 | RIG-I-like receptor signaling pathway | |||
32 | Hematopoietic cell lineage | |||
33 | Natural killer cell mediated cytotoxicity | |||
34 | T cell receptor signaling pathway | |||
35 | Fc epsilon RI signaling pathway | |||
36 | TNF signaling pathway | |||
37 | Type II diabetes mellitus | |||
38 | Non-alcoholic fatty liver disease (NAFLD) | |||
39 | Type I diabetes mellitus | |||
40 | Alzheimer's disease | |||
41 | Amyotrophic lateral sclerosis (ALS) | |||
42 | Pertussis | |||
43 | Legionellosis | |||
44 | Leishmaniasis | |||
45 | Chagas disease (American trypanosomiasis) | |||
46 | African trypanosomiasis | |||
47 | Malaria | |||
48 | Amoebiasis | |||
49 | Tuberculosis | |||
50 | Influenza A | |||
51 | HTLV-I infection | |||
52 | Herpes simplex infection | |||
53 | Asthma | |||
54 | Systemic lupus erythematosus | |||
55 | Rheumatoid arthritis | |||
56 | Allograft rejection | |||
57 | Graft-versus-host disease | |||
58 | Hypertrophic cardiomyopathy (HCM) | |||
59 | Dilated cardiomyopathy | |||
60 | Dorso-ventral axis formation | |||
61 | Notch signaling pathway | |||
62 | Thyroid hormone signaling pathway | |||
63 | Prion diseases | |||
64 | Intestinal immune network for IgA production | |||
65 | Autoimmune thyroid disease | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | IL2 Signaling Pathway | |||
3 | IL3 Signaling Pathway | |||
4 | IL4 Signaling Pathway | |||
5 | Leptin Signaling Pathway | |||
6 | RANKL Signaling Pathway | |||
7 | IL1 Signaling Pathway | |||
8 | TSH Signaling Pathway | |||
9 | TNFalpha Signaling Pathway | |||
10 | IL9 Signaling Pathway | |||
11 | TSLP Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | EGF receptor signaling pathway | |||
3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
4 | Interleukin signaling pathway | |||
5 | JAK/STAT signaling pathway | |||
6 | PDGF signaling pathway | |||
7 | Ras Pathway | |||
8 | CCKR signaling map ST | |||
9 | Apoptosis signaling pathway | |||
10 | Wnt signaling pathway | |||
11 | Alzheimer disease-presenilin pathway | |||
12 | Notch signaling pathway | |||
Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
Pathway Interaction Database | GMCSF-mediated signaling events | Click to Show/Hide | ||
2 | IL27-mediated signaling events | |||
3 | Signaling events mediated by PTP1B | |||
4 | IL12-mediated signaling events | |||
5 | Signaling events mediated by TCPTP | |||
6 | Signaling events mediated by HDAC Class I | |||
7 | IL2-mediated signaling events | |||
8 | CXCR4-mediated signaling events | |||
9 | EGF receptor (ErbB1) signaling pathway | |||
10 | IFN-gamma pathway | |||
11 | ErbB1 downstream signaling | |||
12 | ErbB2/ErbB3 signaling events | |||
13 | IL6-mediated signaling events | |||
14 | PDGFR-beta signaling pathway | |||
15 | Neurotrophic factor-mediated Trk receptor signaling | |||
16 | IL23-mediated signaling events | |||
17 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
18 | FGF signaling pathway | |||
19 | RAC1 signaling pathway | |||
20 | Notch-mediated HES/HEY network | |||
21 | IL12 signaling mediated by STAT4 | |||
22 | Canonical NF-kappaB pathway | |||
23 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
24 | Angiopoietin receptor Tie2-mediated signaling | |||
25 | TNF receptor signaling pathway | |||
26 | Ceramide signaling pathway | |||
27 | amb2 Integrin signaling | |||
28 | RXR and RAR heterodimerization with other nuclear receptor | |||
29 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
30 | Caspase Cascade in Apoptosis | |||
31 | Cellular roles of Anthrax toxin | |||
32 | Downstream signaling in naï | |||
33 | ||||
34 | Notch signaling pathway | |||
35 | Presenilin action in Notch and Wnt signaling | |||
36 | Validated transcriptional targets of deltaNp63 isoforms | |||
37 | Regulation of nuclear SMAD2/3 signaling | |||
38 | IL4-mediated signaling events | |||
39 | Glucocorticoid receptor regulatory network | |||
40 | IL5-mediated signaling events | |||
41 | AP-1 transcription factor network | |||
Reactome | Interleukin-6 signaling | Click to Show/Hide | ||
2 | Senescence-Associated Secretory Phenotype (SASP) | |||
3 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
4 | Transcriptional regulation of pluripotent stem cells | |||
5 | Growth hormone receptor signaling | |||
6 | Transcriptional regulation of white adipocyte differentiation | |||
7 | TNFR1-induced proapoptotic signaling | |||
8 | Regulation of TNFR1 signaling | |||
9 | TNFR1-induced NFkappaB signaling pathway | |||
10 | TNFR1-mediated ceramide production | |||
11 | TNFR2 non-canonical NF-kB pathway | |||
12 | TNF signaling | |||
13 | Pre-NOTCH Processing in the Endoplasmic Reticulum | |||
14 | Pre-NOTCH Transcription and Translation | |||
15 | Pre-NOTCH Processing in Golgi | |||
16 | NOTCH1 Intracellular Domain Regulates Transcription | |||
17 | Activated NOTCH1 Transmits Signal to the Nucleus | |||
18 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||
19 | Constitutive Signaling by NOTCH1 t(7 | |||
20 | M1580_K2555) Translocation Mutant | |||
21 | Constitutive Signaling by NOTCH1 HD Domain Mutants | |||
22 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||
23 | Notch-HLH transcription pathway | |||
24 | GPVI-mediated activation cascade | |||
25 | G beta:gamma signalling through PI3Kgamma | |||
26 | Interleukin-3, 5 and GM-CSF signaling | |||
27 | RAF/MAP kinase cascade | |||
28 | Interleukin receptor SHC signaling | |||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | Click to Show/Hide | ||
2 | Notch Signaling Pathway | |||
3 | Interferon type I signaling pathways | |||
4 | EPO Receptor Signaling | |||
5 | TGF Beta Signaling Pathway | |||
6 | IL-2 Signaling Pathway | |||
7 | EGF/EGFR Signaling Pathway | |||
8 | IL-4 Signaling Pathway | |||
9 | IL-6 signaling pathway | |||
10 | Signaling of Hepatocyte Growth Factor Receptor | |||
11 | Kit receptor signaling pathway | |||
12 | Nuclear Receptors Meta-Pathway | |||
13 | Estrogen Receptor Pathway | |||
14 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
15 | IL-3 Signaling Pathway | |||
16 | Dopaminergic Neurogenesis | |||
17 | Transcriptional regulation of pluripotent stem cells | |||
18 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
19 | Signaling by SCF-KIT | |||
20 | Interleukin-6 signaling | |||
21 | Growth hormone receptor signaling | |||
22 | JAK/STAT | |||
23 | PDGF Pathway | |||
24 | BDNF signaling pathway | |||
25 | Oncostatin M Signaling Pathway | |||
26 | Adipogenesis | |||
27 | Interleukin-11 Signaling Pathway | |||
28 | AGE/RAGE pathway | |||
29 | Prostate Cancer | |||
30 | TSLP Signaling Pathway | |||
31 | IL-9 Signaling Pathway | |||
32 | IL17 signaling pathway | |||
33 | IL-7 Signaling Pathway | |||
34 | Regulation of Microtubule Cytoskeleton | |||
35 | Leptin signaling pathway | |||
36 | TSH signaling pathway | |||
37 | Cell Differentiation - Index | |||
38 | Cell Differentiation - meta | |||
39 | Signaling by PDGF | |||
40 | NGF signalling via TRKA from the plasma membrane | |||
41 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
42 | MicroRNAs in cardiomyocyte hypertrophy | |||
43 | Physiological and Pathological Hypertrophy of the Heart | |||
44 | Androgen receptor signaling pathway | |||
45 | IL-5 Signaling Pathway | |||
46 | Toll-like receptor signaling pathway | |||
47 | Monoamine Transport | |||
48 | SIDS Susceptibility Pathways | |||
49 | Cytokines and Inflammatory Response | |||
50 | MAPK Signaling Pathway | |||
51 | EV release from cardiac cells and their functional effects | |||
52 | FAS pathway and Stress induction of HSP regulation | |||
53 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
54 | Cardiac Hypertrophic Response | |||
55 | Transcriptional Regulation of White Adipocyte Differentiation | |||
56 | Aryl Hydrocarbon Receptor | |||
57 | Apoptosis | |||
58 | Nanoparticle triggered regulated necrosis | |||
59 | Amyotrophic lateral sclerosis (ALS) | |||
60 | Allograft Rejection | |||
61 | TNF alpha Signaling Pathway | |||
62 | TWEAK Signaling Pathway | |||
63 | Extrinsic Pathway for Apoptosis | |||
64 | Folate Metabolism | |||
65 | Vitamin B12 Metabolism | |||
66 | Selenium Micronutrient Network | |||
67 | Regulation of toll-like receptor signaling pathway | |||
68 | Matrix Metalloproteinases | |||
69 | Gene regulatory network modelling somitogenesis | |||
70 | Endoderm Differentiation | |||
71 | Hematopoietic Stem Cell Differentiation | |||
72 | Differentiation Pathway | |||
73 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
74 | Pre-NOTCH Expression and Processing | |||
75 | Signaling by NOTCH1 | |||
76 | Notch Signaling Pathway | |||
77 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
78 | Cardiac Progenitor Differentiation | |||
79 | Gastric Cancer Network 1 | |||
80 | Neural Crest Differentiation | |||
81 | miR-targeted genes in muscle cell - TarBase | |||
82 | miR-targeted genes in lymphocytes - TarBase | |||
83 | miR-targeted genes in epithelium - TarBase | |||
84 | Regulation of beta-cell development | |||
85 | Generic Transcription Pathway | |||
86 | Heart Development | |||
87 | Inflammatory Response Pathway | |||
88 | Interleukin-2 signaling | |||
89 | Interleukin-3, 5 and GM-CSF signaling |